Sun Pharma Advanced Research Company Limited (SPARC) - Total Assets
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) holds total assets worth Rs3.22 Billion INR (≈ $34.87 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Sun Pharma Advanced Research Company Lim to assess how comfortably operating cash covers total debt obligations.
Sun Pharma Advanced Research Company Limited - Total Assets Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's total assets have evolved over time, based on quarterly financial data. See Sun Pharma Advanced Research Company Lim (SPARC) net assets for net asset value and shareholders' equity analysis.
Sun Pharma Advanced Research Company Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Sun Pharma Advanced Research Company Limited's total assets of Rs3.22 Billion consist of 7.8% current assets and 92.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.6% |
| Accounts Receivable | Rs160.60 Million | 4.8% |
| Inventory | Rs19.54 Million | 0.6% |
| Property, Plant & Equipment | Rs992.55 Million | 29.6% |
| Intangible Assets | Rs536.50 Million | 16.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Sun Pharma Advanced Research Company Lim.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sun Pharma Advanced Research Company Limited's current assets represent 7.8% of total assets in 2025, a decrease from 45.8% in 2007.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2025, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.6% of total assets.
Sun Pharma Advanced Research Company Limited Competitors by Total Assets
Key competitors of Sun Pharma Advanced Research Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Sun Pharma Advanced Research Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.32 | 0.28 |
| Quick Ratio | 0.03 | 0.32 | 0.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs-4.77 Billion | Rs-1.88 Billion | Rs-1.74 Billion |
Sun Pharma Advanced Research Company Limited - Advanced Valuation Insights
This section examines the relationship between Sun Pharma Advanced Research Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 56.32 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | Rs3.36 Billion |
| Market Capitalization | $729.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sun Pharma Advanced Research Company Limited's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sun Pharma Advanced Research Company Limited's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual total assets of Sun Pharma Advanced Research Company Limited from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs3.36 Billion ≈ $36.29 Million |
-34.85% |
| 2024-03-31 | Rs5.15 Billion ≈ $55.70 Million |
-37.96% |
| 2023-03-31 | Rs8.30 Billion ≈ $89.77 Million |
+196.38% |
| 2022-03-31 | Rs2.80 Billion ≈ $30.29 Million |
+21.94% |
| 2021-03-31 | Rs2.30 Billion ≈ $24.84 Million |
-15.73% |
| 2020-03-31 | Rs2.73 Billion ≈ $29.48 Million |
-31.60% |
| 2019-03-31 | Rs3.98 Billion ≈ $43.09 Million |
+29.04% |
| 2018-03-31 | Rs3.09 Billion ≈ $33.40 Million |
+12.69% |
| 2017-03-31 | Rs2.74 Billion ≈ $29.64 Million |
+68.47% |
| 2016-03-31 | Rs1.63 Billion ≈ $17.59 Million |
+14.01% |
| 2015-03-31 | Rs1.43 Billion ≈ $15.43 Million |
-22.27% |
| 2014-03-31 | Rs1.84 Billion ≈ $19.85 Million |
-12.18% |
| 2013-03-31 | Rs2.09 Billion ≈ $22.60 Million |
+144.08% |
| 2012-03-31 | Rs856.26 Million ≈ $9.26 Million |
+10.49% |
| 2011-03-31 | Rs774.98 Million ≈ $8.38 Million |
+7.28% |
| 2010-03-31 | Rs722.39 Million ≈ $7.81 Million |
+17.36% |
| 2009-03-31 | Rs615.53 Million ≈ $6.66 Million |
+0.07% |
| 2008-03-31 | Rs615.09 Million ≈ $6.65 Million |
+11.31% |
| 2007-03-31 | Rs552.58 Million ≈ $5.98 Million |
-- |
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more